Ajjai S Alva
Maizel Research Professor of Translational/Clinical Oncology
Clinical Professor of Internal Medicine
[email protected]

Available to mentor
Ajjai S Alva
Clinical Professor
  • About
  • Qualifications
  • Center Memberships
  • Research Overview
  • Recent Publications
    • About

    Maisel Research Professor of Clinical and Translational Oncology
    Clinical Professor, Division of Hematology Oncology, Department of Internal Medicine
    Steering Committee Member, ORP NCCN
    University of Michigan Rogel Comprehensive Cancer Center
    Physician Co-Lead, GU Oncology Disease Group
    Hematology-Oncology Peer Review Committee GU Member
    Hematology-Oncology Coordination Committee Member

    Qualifications
    • MS Cell Biology Molecular Genetics
      University of Maryland, College Park, College Park, 2004
    • MB BS
      Jawaharlal Institute of Postgraduate Medical Education and Research, Dhanvantari Nagar, 2000
    • FASCO
      American Society of Clinical Oncology, Alexandria
    Center Memberships
    • Center Member
      Rogel Cancer Center
    Research Overview

    GU oncology Therapeutics
    Biomarkers including ctDNA, Genomics
    Radiomics in Immunotherapy
    Clinical Trials
    Mentoring Trainees in Clinical Research

    Recent Publications See All Publications
    • Journal Article
      Impact of contemporary patterns of chemotherapy utilization on survival in patients with advanced cancer of the urinary tract: a Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC).
      Bamias A, Tzannis K, Harshman LC, Crabb SJ, Wong Y-N, Kumar Pal S, De Giorgi U, Ladoire S, Agarwal N, Yu EY, Niegisch G, Necchi A, Sternberg CN, Srinivas S, Alva A, Vaishampayan U, Cerbone L, Liontos M, Rosenberg J, Powles T, Bellmunt J, Galsky MD, RISC Investigators . Ann Oncol, 2019 Nov 1; 30 (11): 1841 DOI:10.1093/annonc/mdz214
      PMID: 31868903
    • Proceeding / Abstract / Poster
      Abstract 730: Genomic characterization of hereditary leiomyomatosis and renal cell carcinoma (HLRCC), a rare and aggressive kidney cancer
      Vats P, Zhang Y, Dhanashekaran SM, Pandi NS, Cao X, Su F, Shukla S, Wang R, Cieslik M, Pan J, Ricketts CJ, Kumpati PK, Alva A, Linehan MW, Mehra R, Chinnaiyan AM. Cancer Research, 2019 Jul 1; 79 (13_Supplement): 730 - 730. DOI:10.1158/1538-7445.am2019-730
    • Proceeding / Abstract / Poster
      Abstract 730: Genomic characterization of hereditary leiomyomatosis and renal cell carcinoma (HLRCC), a rare and aggressive kidney cancer
      Vats P, Zhang Y, Dhanashekaran SM, Pandi NS, Cao X, Su F, Shukla S, Wang R, Cieslik M, Pan J, Ricketts CJ, Kumpati PK, Alva A, Linehan MW, Mehra R, Chinnaiyan AM. 2019 Jul 1; 730 - 730. DOI:10.1158/1538-7445.sabcs18-730
    • Proceeding / Abstract / Poster
      Impact of timing of adjuvant chemotherapy following radical cystectomy for bladder cancer on patient survival.
      Grunewald CM, Henn A, Galsky MD, Plimack ER, Harshman LC, Yu EY, Crabb SJ, Pal SK, Alva AS, Powles T, De Giorgi U, Agarwal N, Bamias A, Ladoire S, Necchi A, Vaishampayan UN, Sternberg CN, Bellmunt J, Baniel J, Niegisch G. Journal of Clinical Oncology, 2019 May 20; 37 (15_suppl): e16017 - e16017. DOI:10.1200/jco.2019.37.15_suppl.e16017
    • Proceeding / Abstract / Poster
      Nomogram-based risk prediction of local and distant relapse after radical cystectomy, and role of perioperative chemotherapy, in patients with muscle-invasive bladder cancer (MIBC): A multicenter study.
      Necchi A, Pond GR, Plimack ER, Niegisch G, Yu EY, Pal SK, Bamias A, Agarwal N, Alva AS, Srinivas S, Crabb SJ, Vaishampayan UN, Bowles DW, Berthold DR, Theodore C, Sridhar SS, Powles T, Rosenberg JE, Bellmunt J, Galsky MD. Journal of Clinical Oncology, 2018 Feb 20; 36 (6_suppl): 448 - 448. DOI:10.1200/jco.2018.36.6_suppl.448
    • Proceeding / Abstract / Poster
      Pazopanib with low fat meal (PALM) in advanced renal cell carcinoma (RCC).
      Reimers MA, Daignault S, Shango M, Dedinsky R, Riddle L, Wen B, Redman BG, Alva AS. Journal of Clinical Oncology, 2018 Feb 20; 36 (6_suppl): 683 - 683. DOI:10.1200/jco.2018.36.6_suppl.683
    • Proceeding / Abstract / Poster
      Phase II trial of palbociclib (PD-0332991) in patients with metastatic urothelial cancer (UC) after failure of first-line chemotherapy.
      Rose TL, Chism DD, Alva AS, Deal AM, Maygarden S, Whang YE, Kardos J, Drier A, Kim WY, Milowsky MI. Journal of Clinical Oncology, 2018 Feb 20; 36 (6_suppl): 500 - 500. DOI:10.1200/jco.2018.36.6_suppl.500
    • Proceeding / Abstract / Poster
      Radium-223 and atezolizumab in platinum refractory urothelial carcinoma with bone metastases: NCT03208712.
      Yentz SE, Reimers MA, Daignault S, Piert M, Alva AS. Journal of Clinical Oncology, 2018 Feb 20; 36 (6_suppl): tps543 - tps543. DOI:10.1200/jco.2018.36.6_suppl.tps543